Baird Initiates Coverage On Axsome Therapeutics with Outperform Rating, Announces Price Target of $108

Benzinga · 03/19 08:48
Baird analyst Joel Beatty initiates coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Outperform rating and announces Price Target of $108.